Sign up to save your podcasts
Or
Share 58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study
Discussão do artigo: "Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo controlled, phase 3 study" de Wang M Lancet Oncology 2025
Apresentado por: Dr. Guilherme Rodrigues
Discussão por: Dr. Eduardo Burlamaqui, Dr. Lucas Salviano, Dr. Pedro Moraes e Dr. Vinícius Molla
View all episodes
By TMO EPM / Hemato H9JDiscussão do artigo: "Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo controlled, phase 3 study" de Wang M Lancet Oncology 2025
Apresentado por: Dr. Guilherme Rodrigues
Discussão por: Dr. Eduardo Burlamaqui, Dr. Lucas Salviano, Dr. Pedro Moraes e Dr. Vinícius Molla